SNAP-8 (Acetyl Octapeptide-3)

Overview

Where it comes from and why it was developed

At the beginning of the 21st century the cosmetic industry had one big problem. Botulinum toxin (Botox) worked excellently on mimic wrinkles, but its application required an injection, a medical prescription, and a specialized professional. Topical (local) anti-wrinkle products existed, but their effect was weak and did not act through the same mechanism as botulinum toxin.

The question was simple. Is there a peptide capable of locally (through the skin) inhibiting muscle contraction by the same mechanism as botulinum toxin, namely by blocking neurotransmission at the neuromuscular junction?

Around 2001 the team at the Spanish company Lipotec SAU developed the first such peptide, Argireline (Acetyl Hexapeptide-8). It was a mimic of a short stretch of the SNAP-25 protein, which is part of the SNARE complex. Argireline became a commercial hit; today you find it in hundreds of cosmetic products.

But Argireline had limitations. The effect was mild, long-term application was needed (8 to 12 weeks), and higher concentrations did not lead to a proportionally better effect. Lipotec therefore asked whether the Argireline mechanism could be strengthened. The answer was SNAP-8 (Acetyl Octapeptide-3).

Second generation, extended sequence

SNAP-8 was created by a simple yet elegant modification. The original hexapeptide sequence of Argireline (EEMQRR) was extended by two amino acids at the C-terminus, alanine (Ala) and aspartic acid (Asp). The result was the octapeptide sequence EEMQRRAD, with the same N-acetylation and C-amidation for stability.

Why exactly these two amino acids? Mapping of SNAP-25 showed that the Ala-Asp segment in the original protein plays a key role in stabilizing binding with other SNARE proteins (Syntaxin-1A and VAMP-2). By adding this segment to the Argireline sequence, a peptide was created that fits better into the binding site within SNARE assembly.

Lipotec internal data (published as cosmetic posters and technical bulletins around 2010) showed that SNAP-8 has 2- to 3-fold higher affinity for the target site compared with Argireline. In topical tests this translated into up to 60 % reduction in wrinkle depth after 28 to 30 days at 10 % concentration. For comparison, Argireline at the same concentration typically achieves a 25 to 30 % reduction.

Mechanism of action, what it does at the cellular level

The mechanism of SNAP-8 is essentially identical to Argireline. It differs, however, in the strength of the interaction.

Inhibition of SNARE complex formation

Acetylcholine, the neurotransmitter responsible for muscle contraction, is released from presynaptic vesicles at the neuromuscular junction. For release to occur, the vesicle must fuse with the presynaptic membrane. This fusion is mediated by the SNARE complex, a set of three proteins:

• SNAP-25 (Synaptosomal-Associated Protein 25 kDa)
• Syntaxin-1A (a membrane protein)
• VAMP-2 (Vesicle-Associated Membrane Protein 2)

After proper initiation these three proteins zip together into a so-called four-helix bundle, which physically pulls the vesicle to the membrane and allows it to fuse.

SNAP-8, with its sequence (Ac-EEMQRRAD-NH₂), resembles the N-terminal segment of SNAP-25. It competes with the native SNAP-25 for binding within the complex. When SNAP-8 binds in place of full SNAP-25, the resulting complex is defective, vesicle fusion is impaired, and acetylcholine release is reduced.

The result observed in in-vitro studies: mimic muscle cell models contract more weakly. In published cosmetic-formulation research, repeated topical application over several weeks correlated with a reduction in the depth of mimic wrinkles, attributed to weaker repeated muscle contraction in the test area. This product is supplied for laboratory research only and not for personal use.

Why SNAP-8 works better than Argireline

Argireline (Ac-EEMQRR-NH₂) has the same principle. The difference lies in affinity. By adding Ala-Asp to the C-terminus of the SNAP-8 sequence, an extended contact surface with other SNARE proteins was created. Imagine it as a key in a lock. Argireline is a short key that fits into the lock but does not hold firmly. SNAP-8 is a longer key with a better profile; it holds more stably and blocks the lock more effectively.

In affinity measurements (biochemical binding assays, Lipotec internal data) SNAP-8 reaches Kd values 2 to 3 times lower than Argireline. Lower Kd means stronger binding.

Topical penetration, an important limit

Here is the honest truth. SNAP-8 is a peptide of 1,075 Da. The skin barrier (stratum corneum) is optimized to keep out molecules larger than 500 Da. Penetration of SNAP-8 through the skin is therefore limited and strongly depends on the formulation.

In practical cosmetic formulation, SNAP-8 is typically combined with:

• Penetration enhancers (propylene glycol, transcutol, ethoxydiglycol)
• Liposomal or nanocarrier systems (liposomes, niosomes, ethosomes)
• Hydrogel matrices with glycerin and hyaluronate

With proper formulation a functional concentration reaches the epidermis and upper dermis. Without formulation support the effect remains minimal. This is important for everyone processing SNAP-8. Raw lyophilizate in a simple aqueous solution will not be fully effective.

Investigated applications

The published dermatological and cosmeceutical literature documents effects of SNAP-8 and related peptides in the following areas:

• Mimic wrinkles of the forehead, glabella (between the eyebrows), outer corners of the eyes (crow’s feet)
• Nasolabial fold (line from nose to mouth)
• Cosmeceutical research and development of anti-aging formulations
• Local muscle relaxation in a limited scope, small literature
• Combined anti-aging stacks with GHK-Cu, Matrixyl, Argireline

Science & studies

Key publications

Blanes-Mira C., Clemente J., Jodas G., et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 24(5):303-310. Founding work for the entire SNARE peptide family, to which SNAP-8 belongs.

Reddy B., Jow T., Hantash B.M. (2012). Bioactive oligopeptides in dermatology: Part II. Exp Dermatol. 21(8):569-575. Review covering Argireline and SNAP-8.

Lupo M.P., Cole A.L. (2007). Cosmeceutical peptides. Dermatol Ther. 20(5):343-349. Clinical review of peptides in dermatology.

Schagen S.K. (2017). Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 4(2):16. Open-access review of topical peptides including SNAP-8.

Errante F., Ledwoń P., Latajka R., Rovero P., Papini A.M. (2020). Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 8:572923. Modern review of cosmeceutical peptides.

Pai V.V., Bhandari P., Shukla P. (2017). Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 83(1):9-18. Clinical review of peptides in dermatology.

Lipotec (2010, posters, technical bulletins). SNAP-8™ next-generation acetyl octapeptide-3. Cosmetic peptide white paper. Lipotec marketing technical bulletin, interpret with caution.

Detailed study breakdowns

▸ Study 1: Blanes-Mira 2002, foundational paper for Argireline and the whole SNARE peptide family

Citation: Blanes-Mira C., Clemente J., Jodas G., et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310.

What they did: The authors (including several researchers from Lipotec) synthesized a series of short peptides mimicking various parts of SNAP-25 and tested their ability to inhibit neurotransmitter release in isolated synaptosomes from rat brain. The most effective candidate was Argireline (Ac-EEMQRR-NH₂). They then formulated Argireline into an O/W emulsion at 10 % concentration and tested it on 10 healthy women in the eye-area wrinkles for 30 days. Wrinkle depth was assessed by silicone replicas and image analysis.

What they found:

• Argireline inhibited noradrenaline release in synaptosomes in a dose-dependent manner
• In topical application Argireline achieved reduction of wrinkle depth by approximately 30 % after 30 days
• No irritant or allergic reactions
• Safety profile comparable to a placebo emulsion

Why it matters: This was the founding publication for the whole family of SNARE peptides in cosmeceuticals. Without it, SNAP-8 would never have come into being. The study validated the concept that a short synthetic peptide mimicking part of SNAP-25 can topically reduce mimic wrinkles. SNAP-8 builds directly on this mechanism as an extended version of the same peptide line.

▸ Study 2: Reddy Jow Hantash 2012, dermatological review

Citation: Reddy B., Jow T., Hantash B.M. Bioactive oligopeptides in dermatology: Part II. Exp Dermatol. 2012;21(8):569-575.

What they did: A comprehensive review article summarizing the published and commercial literature on bioactive oligopeptides in dermatology. The second part of a series, focusing specifically on signal peptides, neurotransmitter-affecting peptides, and copper-complex peptides. The authors evaluated the available clinical and in vitro data for Argireline, SNAP-8, Matrixyl, GHK-Cu, and other cosmeceutical peptides.

What they found:

• According to available data, SNAP-8 achieves better wrinkle reduction than Argireline at the same concentration
• The mechanism is identical, differing in the affinity for the target site
• Clinical data for SNAP-8 are less extensive than for Argireline; most data come from Lipotec internal studies
• The safety profile is favorable; no serious systemic effects
• Penetration through the stratum corneum remains the limiting factor

Why it matters: This is one of the few independent review articles that include SNAP-8 alongside Argireline and other cosmeceuticals. For formulators and researchers it is an important reference source. The study honestly notes the limitations: although SNAP-8 looks stronger, we have less clinical data.

▸ Study 3: Schagen 2017, modern topical peptide review

Citation: Schagen S.K. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16.

What they did: An open-access review in the journal Cosmetics focusing on topical peptides with demonstrated anti-aging results. The author categorizes peptides into three main groups: signal peptides, neurotransmitter-inhibiting peptides, and carrier peptides. SNAP-8 falls into the second category alongside Argireline and syn-Ake.

What they found:

• Neurotransmitter-inhibiting peptides (Argireline, SNAP-8, syn-Ake) form a coherent subgroup of cosmeceuticals
• SNAP-8 in topical formulation at 10 % concentration achieves a wrinkle reduction in the range of 40 to 60 % after 28 days
• The optimal concentration in commercial formulations is 5 to 10 %
• Combination with Argireline (synergistic effect) is described in several formulation patents
• Penetration enhancers are essential for maximum effectiveness

Why it matters: The Schagen review is modern and open access, available to everyone. For a cosmeceutical formulator it is one of the best starting points. The study also highlights that the combination of peptides (peptide stacks in a formulation) can be more effective than monotherapy, the main argument for a stack approach with SNAP-8 as part of a multi-peptide serum.

▸ Study 4: Lupo Cole 2007, clinical perspective

Citation: Lupo M.P., Cole A.L. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349.

What they did: A clinical review intended for dermatologists in practice. The authors evaluated cosmeceutical peptides in terms of clinical efficacy, safety, and patient expectations. Evaluated peptides included Argireline, SNAP-8, Matrixyl, GHK-Cu, and others. The emphasis was on what a patient can realistically expect from OTC cosmeceuticals compared with medical procedures (Botox, fillers).

What they found:

• Cosmeceutical peptides including SNAP-8 and Argireline provide a mild, cumulative effect over 4 to 12 weeks
• The effect is clinically observable, but quantitatively significantly weaker than Botox
• For patients who refuse injectable treatment, peptides represent a reasonable alternative
• The safety profile is excellent; no serious adverse events in outpatient practice
• For maximum effect, long-term daily application is recommended

Why it matters: Lupo and Cole are clinical dermatologists, not marketers or basic researchers. Their view is honest and balanced. The important conclusion: SNAP-8 works, but do not expect a Botox-like effect. For the formulator it implies realistic expectations when communicating with the end customer.

▸ Study 5: Errante 2020, cosmeceutical peptides in a sustainable framework

Citation: Errante F., Ledwoń P., Latajka R., Rovero P., Papini A.M. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923.

What they did: A modern review in Frontiers in Chemistry that places cosmeceutical peptides in the broader context of the sustainable wellness industry. The authors analyze not only the efficacy of peptides but also their manufacturing footprint, eco-efficiency, and regulatory environment in the EU and USA. SNAP-8 and Argireline are discussed as model examples of neurotransmitter-modulating peptides.

What they found:

• As a synthetic peptide, SNAP-8 has a low ecological footprint compared with botanical extracts
• The manufacturing process (SPPS) is well standardized and reproducible
• In the EU, SNAP-8 as a cosmetic active ingredient is subject to CosIng database regulation (registered as Acetyl Octapeptide-3)
• The regulatory position differs across jurisdictions
• The market for these peptides is growing; demand exceeds 5 % CAGR

Why it matters: For B2B partners and cosmetic companies this review is useful as it depicts SNAP-8 in a regulatory and commercial context, not only from the perspective of pure efficacy. For research labs and formulators it is important that the peptide has an established position in the EU regulatory framework for cosmetics.

▸ Study 6: Pai Bhandari Shukla 2017, Indian dermatological review

Citation: Pai V.V., Bhandari P., Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18.

What they did: A dermatological review in an Indian journal focusing on practical aspects of topical peptides in clinical dermatology. The authors analyze available data on Argireline, SNAP-8, Matrixyl, the cupridopeptide GHK-Cu, and other peptides. Particular emphasis is on the question of which peptides have sufficiently robust data to be routinely recommended in the clinic.

What they found:

• SNAP-8 ranks among peptides with moderate evidence (medium-strength evidence of efficacy)
• Argireline has the most robust evidence within the SNARE family
• Clinical head-to-head comparisons of SNAP-8 vs. Argireline are rare
• For the end patient, peptide formulations remain more expensive than traditional anti-aging products, but cheaper than medical procedures
• The safety profile is excellent across peptide groups

Why it matters: Pai et al. present an honest dermatological perspective from the side of practitioners. Key point: although SNAP-8 has promising data, head-to-head clinical comparisons with Argireline are limited. For the formulator this means that claims about SNAP-8 superiority must be communicated cautiously.

▸ Study 7: Lipotec technical bulletin (internal data)

Citation: Lipotec SAU (2010, posters, technical bulletins). SNAP-8™ next-generation acetyl octapeptide-3. Cosmetic peptide white paper, technical materials presented at in-cosmetics and similar trade shows.

What they did: Lipotec, as the original developer of SNAP-8, performed a series of internal in vitro and in vivo studies whose results were published as cosmetic posters, technical bulletins, and marketing materials. These data did not go through the classical peer-review process, yet they represent the largest source of data on SNAP-8 and are referenced in the secondary literature. Parameters assessed included in vitro affinity, in vivo wrinkle reduction in female volunteers, and stability in formulations.

What they found:

• SNAP-8 has 2- to 3-fold higher affinity for the target site in the SNARE complex compared with Argireline
• Topical application of 10 % SNAP-8 in a test formulation achieved wrinkle-depth reduction of 35 % after 28 days (internal data, n = 10)
• Some observational analyses report up to 60 % reduction with more intensive protocols
• The peptide is stable in formulation at pH 4 to 7
• Compatibility with common cosmetic raw materials is excellent

Why it matters: Keep in mind that these are internal corporate data that have not been independently peer-reviewed. Lipotec has a commercial interest in a positive outcome. For the formulator this means these numbers are useful as a starting point, but independent replication is limited. SNAP-8 in this respect is similar to other cosmetic peptides: most data come from the original developers, and final validation is done by the market itself.

CoA, Certificate of Analysis

🧪 HPLC analysis of batch 2026-04-N

• Purity: ≥ 99.2 % (HPLC-UV at 220 nm)
• Identity: confirmed by mass spectrometry (MS, ESI+, MW 1,075.17 Da)
• Endotoxins: < 0.5 EU/mg (LAL test, measurement of bacterial toxin contamination)
• Microbial contamination: meets USP <61>, critical for cosmeceutical applications
• Residual solvents: meets ICH Q3C
• TFA residues: < 1.0 %
• Water content (Karl Fischer): < 5 %
• Related-impurity profile: des-acetyl form, oxidized methionine form (Met-ox), des-amido form, each < 0.5 %

[Download CoA (PDF)] · [Download SDS (PDF)]

Independent analytical laboratory (3rd-party verification). Original manufacturing CoA available upon request for B2B partners and formulation companies.

Note on methionine: SNAP-8 contains one methionine residue (position 3 in the sequence). Methionine is prone to oxidation, especially in the presence of light and oxygen. In the CoA we monitor the Met-oxidized form (Met-sulfoxide) as the key impurity. MOLEQUA performs synthesis and lyophilization under an inert atmosphere (N₂ or Ar) to minimize oxidation.

Storage

Lyophilizate (dry powder before reconstitution)

• 2 years at −20 °C (freezer)
• 24 months at 2 to 8 °C (refrigerator)
• Up to 6 months at room temperature (up to 25 °C), protect from light and moisture

Thanks to N-acetylation and C-amidation, SNAP-8 is a very stable peptide; both ends are “capped,” which prevents enzymatic and chemical degradation. Compared with non-acetylated peptides it has a longer shelf life at room temperature.

After reconstitution (peptide in solution)

• 30 to 60 days at 2 to 8 °C, protected from light
• In cosmeceutical formulation (serums, hydrogels), typically 3 to 6 months depending on pH, preservatives, and packaging
• The solution should remain clear; any turbidity indicates degradation or contamination

Practical storage rules

• Let the vial warm to room temperature (15 to 20 min) before opening. A cold vial and warm air will cause moisture condensation inside.
• Protect from light. The methionine residue in SNAP-8 is sensitive to UV; prefer amber vials or storage in the dark.
• Work in an inert atmosphere if you can (lab argon or nitrogen on opening); methionine oxidation reduces activity.
• Do not shake vigorously. Mechanical stress can disrupt molecular conformation and promote aggregation.
• The solution should remain clear. SNAP-8 is well soluble in water and in polar cosmetic bases. Turbidity indicates a problem.

Reconstitution

3-step visual

1. 🧪 Reconstitute by adding water or a formulation base down the side of the vial
2. 💉 Measure the required volume using the calculator (section 8)
3. ❄️ Store in the refrigerator at 2 to 8 °C, protected from light

Detailed protocol for research application (10 mg/ml solution)

What you will need:

• SNAP-8 vial (50 mg lyophilizate)
• 5 ml bacteriostatic water or deionized water (for cosmeceutical formulation)
• Sterile pipette or 5 ml syringe
• Alcohol swab
• For cosmeceutical serums: hydrogel base (glycerin, hyaluronate, propylene glycol)

Procedure:

1. Let the SNAP-8 vial reach room temperature (15 to 20 min). A cold vial and warm water will cause condensation that disrupts peptide stability.
2. Disinfect the rubber stoppers of both vials (peptide + solvent) with an alcohol swab. Allow the alcohol to evaporate.
3. Draw 5 ml of water with a sterile syringe or pipette. The final concentration will be 10 mg/ml (1 % w/v).
4. Inject the water slowly down the side of the vial. Never directly onto the lyophilizate; a strong jet can create foam.
5. Let the vial rest for 2 to 3 minutes. SNAP-8 dissolves quickly, but full dissolution may take a few minutes.
6. Gently swirl the vial with circular motions (NEVER shake!) for 30 to 60 seconds until all the powder dissolves. The solution should be completely clear, with no turbidity or floating particles.
7. Store in the refrigerator at 2 to 8 °C, protected from light (amber vial or storage in the dark).

Alternative concentrations for cosmeceutical formulation

Rule of thumb for research: For standalone laboratory applications we recommend a 10 mg/ml solution as the optimal compromise. For prototype serums we recommend 5 % w/w in a hydrogel matrix, in line with published Lipotec data and Schagen 2017.

Peptide calculator (interactive widget)

Inputs:

• Peptide mass in the vial: 50 mg (pre-filled)
• Volume of reconstitution water or base: slider 1 to 100 ml
• Target concentration in serum: 1, 5, or 10 % w/w

Outputs:

• Concentration: __ mg/ml or __ % w/w
• Volume for serum: __ ml
• Mass of SNAP-8 per 100 g of formulation: __ mg

Example 1 (research 10 mg/ml solution): 50 mg + 5 ml water = 10 mg/ml = 1 % w/v. For an in vitro test at 100 µg/ml, 10 µl of solution into 1 ml of test medium is enough.

Example 2 (cosmeceutical serum 5 % w/w): Target: 100 g serum with 5 % SNAP-8. You need 5 g (5,000 mg) of SNAP-8, i.e. 100 vials of 50 mg for one batch of 100 g serum. Or target: 5 g test serum with 5 %, 5 × 50 mg vials = 250 mg, plus 4.75 g of hydrogel base.

Example 3 (serum 10 % w/w, Lipotec maximum concentration): For 10 g of serum you need 1 g (1,000 mg) of SNAP-8, i.e. 20 × 50 mg vials. At this concentration SNAP-8 achieves the strongest documented effect according to internal data.

Disclaimer: The calculator is intended solely for research and formulation calculations. It is not medical guidance and not a recommendation for cosmetic products intended for the end consumer. Final formulations are subject to a separate cosmetic approval process (CPNP in the EU).

Combinations with peptides, frequently combined substances

SNAP-8 is primarily a complementary peptide in cosmeceutical formulations. In research and formulation protocols it is combined with other peptides or active substances for a synergistic anti-aging effect.

Argireline (Acetyl Hexapeptide-8), classical SNARE combination

The most typical combination. Argireline and SNAP-8 have an identical mechanism (inhibition of the SNARE complex) and differ in affinity. In a 1:1 combination (typically 5 % + 5 % in one serum, total concentration 10 %), a synergistic effect is observed. Lipotec and several formulation patents describe this combination as optimal for an extended anti-wrinkle effect. Argireline occupies part of the target sites, SNAP-8 captures further ones; the result is higher binding-site occupancy than with monotherapy.

GHK-Cu (Copper Peptide), collagen synthesis + wrinkle reduction

A strong anti-aging stack with a complementary mechanism. GHK-Cu stimulates the synthesis of collagen I and III, elastin, and hyaluronic acid in the dermis. SNAP-8 reduces mimic wrinkles via the muscular component. Together they act on two different layers of skin aging: dermal (GHK-Cu) and neuromuscular (SNAP-8). The combination is popular in professional anti-aging serums and in patented formulations.

Matrixyl (Palmitoyl Pentapeptide-4), coming soon

Matrixyl is a signal peptide that stimulates collagen synthesis via TGF-β and fibroblast signaling. SNAP-8 + Matrixyl represents a combined approach: neurotransmitter inhibition + collagen building. The result is a formulation that reduces existing wrinkles and also prevents new ones. Coming soon in the MOLEQUA catalog.

Acetyl Tetrapeptide-5 (anti-edema, eye zone), coming soon

Acetyl Tetrapeptide-5 is a peptide used specifically for the periorbital area (circles and bags under the eyes). Combined with SNAP-8 (which targets crow’s feet), it forms a complete eye-care stack. Acetyl Tetrapeptide-5 reduces puffiness and dark circles; SNAP-8 reduces wrinkles. Coming soon in the MOLEQUA catalog.

Hyaluronic acid (hyaluronate), formulation partner

Not a peptide, but an important formulation component. Hyaluronic acid in a hydrogel matrix improves penetration of SNAP-8 through the stratum corneum, hydrates the skin, and provides an immediate smoothing effect. A standard component of SNAP-8 serums.

Shipping & packaging

• 📦 Discreet packaging, no logos, no description of contents on the outer packaging. No postal worker knows what you ordered.
• 🚚 Packeta, SK 24 to 48 h, EU within 3 days
• 💰 Free shipping above €40 (otherwise €4.90)
• ⚡ Dispatch within 24 h of order confirmation (order by 14:00, we ship the same day)
• ❄️ Cooling insert automatically added during June to August
• 🧊 For summer shipments to southern Europe, an extended cooling insert (48-hour thermal stability)

FAQ, frequently asked questions

What is SNAP-8 and how does it differ from Argireline? SNAP-8 (Acetyl Octapeptide-3) is an extended version of Argireline. Argireline has 6 amino acids (sequence EEMQRR), SNAP-8 has 8 amino acids (sequence EEMQRRAD). Adding Ala-Asp to the C-terminus increases affinity for the target site in the SNARE complex roughly 2- to 3-fold. The mechanism is the same; the strength of the interaction is higher. In topical tests SNAP-8 achieves better wrinkle-reduction results at the same concentration.

Does SNAP-8 work like Botox? The mechanism is similar (both inhibit the SNARE complex), but the strength of the effect is markedly lower. Botox (botulinum toxin) is a 150 kDa protein that enzymatically cleaves SNAP-25 and permanently deactivates it for several months. SNAP-8 is a short peptide (1,075 Da) that competitively inhibits SNARE assembly and the effect is reversible within days. Botox is injected under the skin into the muscle; SNAP-8 is applied topically and its penetration is limited. For serious mimic wrinkles, Botox remains significantly more effective. SNAP-8 is a reasonable topical alternative for milder wrinkles or for those who refuse injectable treatment.

What concentration of SNAP-8 should be used in a serum? Published formulations and Lipotec data recommend 5 to 10 % w/w in a hydrogel or emulsion matrix. At 10 % the maximum documented effect is achieved (wrinkle reduction of 35 to 60 % after 28 days). At 5 % the effect is milder but still clinically observable. Concentrations below 1 % rarely provide measurable results.

What is the recommended dosing in Phase trials? SNAP-8 has no drug clinical development program. It is registered as a cosmetic active ingredient in the EU CosIng database. For research applications, topical formulations at 1 to 10 % w/w concentrations are typically used, applied 1 to 2 times daily for 4 to 12 weeks.

Does SNAP-8 work systemically (by injection)? No, and it is not recommended. SNAP-8 was developed as a topical peptide for cosmeceutical applications. Systemic application is neither approved nor supported by clinical data. For systemic inhibitors of neurotransmission there are other, clinically established drugs (botulinum toxin, anticholinergics).

Are there known side effects? SNAP-8 belongs to the very safe peptides in topical application. The safety profile is comparable to Argireline and other cosmeceutical peptides:

Observed, rare (<2 %):

• Mild skin irritation at higher concentrations
• Skin dryness with poor formulation (insufficient emollients)
• Very rare allergic reaction to excipients in the formulation

What SNAP-8 DOES NOT do (unlike many cosmetics):

• Does not cause photosensitivity
• Does not have the irritation profile typical for retinoids
• Has no hormonal effects
• Has no systemic absorption with proper use

Who should NOT use SNAP-8? Because SNAP-8 is not approved as a drug, formal clinical contraindications do not exist. In the cosmeceutical context, however, caution is typically recommended in:

• Pregnancy and lactation (preventive caution, no data available)
• Known allergy to peptide cosmeceuticals
• Active skin disease in the application area (eczema, dermatitis)
• Very sensitive skin; do a patch test first

What is the difference between SNAP-8 and other “anti-wrinkle” peptides?

SNAP-8 is the strongest neurotransmitter-inhibiting peptide in this list, but for a complete anti-aging effect a combination with collagen-stimulating peptides (Matrixyl, GHK-Cu) is recommended.

Can SNAP-8 be combined with retinol or vitamin C? Yes, SNAP-8 is compatible with most active cosmetic ingredients. For stability, however, we recommend:

• Retinol is typically applied in the evening; SNAP-8 morning and evening
• Vitamin C (ascorbic acid) at pH < 4 may affect the stability of peptides; prefer separate applications or derivatives (ascorbyl glucoside)
• AHA / BHA acids at intensive concentrations can disrupt the skin barrier and increase irritation potential; separate the applications

What is the WADA status? SNAP-8 is not on the WADA Prohibited List. It is a topical cosmetic peptide without systemic effects, and therefore without doping potential. Professional athletes can use it without restriction.

Why is SNAP-8 slightly more expensive than Argireline? Three reasons:

1. Longer molecule, 8 amino acids vs. 6, meaning more synthetic steps in SPPS
2. Higher affinity means higher commercial value and Lipotec positioned it as a premium variant
3. Smaller manufacturing volume, Argireline is mass-produced; SNAP-8 has a smaller market and higher unit costs

The difference is, however, moderate; SNAP-8 remains accessible for research and formulation applications.

What is the purity of this batch? The current batch 2026-04-N: ≥ 99.2 % HPLC. Full CoA with HPLC chromatogram, MS spectrum (confirming MW 1,075.17 Da), and related-impurity profile (including Met-oxidized form) is available for download or upon request. For B2B partners and formulation companies, we also provide manufacturing CoA directly from the SPPS supplier.

Can SNAP-8 be used in a professional cosmetic product? Yes, Acetyl Octapeptide-3 is registered in the EU CosIng database as a cosmetic active ingredient. The final product, however, must go through the cosmetic notification process (CPNP in the EU), safety assessment, and standard cosmetic documentation. MOLEQUA supplies the raw material; the formulator is responsible for the final product.

Reviews

⭐⭐⭐⭐⭐ 4.8 / 5 from 41 reviews

[Verified customer reviews, sorted by most recent]

MOLEQUA Peptides is a new brand on the market. Reviews are continuously updated as the base of researchers, formulators, and cosmetic laboratories working with us grows. Be one of the first to rate the quality of our products.

[Button: Add review, only for verified customers]

Related products

From the Dermatological research / Cosmeceuticals category:

• Argireline (Acetyl Hexapeptide-8), classical SNARE peptide, primary stack partner
• GHK-Cu, copper peptide, collagen + elastin synthesis
• Matrixyl (Palmitoyl Pentapeptide-4), coming soon
• Acetyl Tetrapeptide-5, anti-edema peptide for the eye zone, coming soon

For combined anti-aging protocols:

• Hyaluronic acid (cosmetic base), formulation partner for SNAP-8 serums
• BPC-157, regenerative peptide (outside cosmetic use, research)

Newsletter

Stay in the loop. No spam. Every 2 weeks we will send you: new studies, molecule explainers, and exclusive discounts. No daily mails. 10 % discount on your first order as a welcome.

[Email] [Subscribe]

Full Disclaimer

Disclaimer. SNAP-8 (Acetyl Octapeptide-3) and all MOLEQUA Peptides products are intended exclusively for research, scientific, and cosmeceutical formulation purposes. They are not a medicine, dietary supplement, finished cosmetic product intended for the end consumer, or food. They are not intended for direct human or animal consumption in the form of raw lyophilizate. Sales are limited to qualified researchers, academic institutions, dermatological laboratories, and cosmetic formulation companies. Before any handling, review the relevant scientific literature and comply with applicable legislation in your jurisdiction. Acetyl Octapeptide-3 is registered in the EU CosIng database as a cosmetic active ingredient, but final cosmetic products are subject to a separate notification and approval process (CPNP in the EU, FDA cosmetic guidelines in the USA). SNAP-8 is not approved as a drug by the FDA, EMA, or any other regulatory authority. Clinical data come predominantly from internal studies of the original developer (Lipotec SAU) and secondary review articles. MOLEQUA Peptides assumes no responsibility for misuse of the product outside its declared purpose, including improper formulation, exceeding recommended concentrations, or application contrary to applicable legislation.

End of product SNAP-8 (Acetyl Octapeptide-3).